skip to main content
Invitado
Mi portal
Mi Cuenta
Cerrar sesión
Identificarse
This feature requires javascript
Tags
Periódicos Eletrónicos
Libros Eletrónicos
Bases de Datos
Bibliotecas de USP
Ayuda
Ayuda
Idioma:
Inglés
Castellano
Portugués (Brasil)
This feature required javascript
This feature requires javascript
Primo Search
Búsqueda General
Búsqueda General
Colección Física
Colecciones Físicas
Producción Intelectual USP
Producción USP
Search For:
Clear Search Box
Search in:
Búsqueda General
Or hit Enter to replace search target
Or select another collection:
Search in:
Búsqueda General
Búsqueda Avanzada
Búsqueda por Índices
This feature requires javascript
Tipo de recurso
criteria input
en cualquier parte del registro
en el título
como autor/creador
en materias
Fecha de creación
lsr01
lsr02
lsr03
lsr04
Orientador
Show Results with:
en el título
Show Results with:
en cualquier parte del registro
en el título
como autor/creador
en materias
Fecha de creación
lsr01
lsr02
lsr03
lsr04
Orientador
Ver resultados con:
criteria input
que contiene las palabras de la búsqueda
con la frase exacta
empieza por
Ver resultados con:
Sumario
criteria input
Y
O
NO
This feature requires javascript
Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?
Li, Biaoru
Frontiers in immunology, 2022-10, Vol.13, p.973881-973881
[Revista revisada por pares]
Frontiers Media S.A
Texto completo disponible
Citas
Citado por
Recurso en línea
Detalles
Comentarios y Etiquetas
Servicios adicionales
Veces citado
This feature requires javascript
Acciones
Agregar a Mi Portal
Eliminar de Mi Portal
Correo Electrónico
Imprimir
Enlae permanente
Cita bibliográfica
EasyBib
EndNote
RefWorks
Delicious
Exportación RIS
Exportar BibTeX
This feature requires javascript
Título:
Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?
Autor:
Li, Biaoru
Materias:
Immunology
;
personalized immunotherapy
;
solid tumor
;
TIL attacking heterogeneous antigen
;
TIL infiltration
;
TIL quiescence
;
TILs (tumor infiltrating lymphocytes)
Es parte de:
Frontiers in immunology, 2022-10, Vol.13, p.973881-973881
Notas:
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
Edited by: Anna Pasetto, Karolinska Institutet (KI), Sweden
Reviewed by: Daniele Fanale, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Italy; Lianghao Ding, University of Texas Southwestern Medical Center, United States
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
Descripción:
Lymphocytes in tumor tissue are called tumor-infiltrating lymphocytes (TILs), and they play a key role in the control and treatment of tumor diseases. Since the discovery in 1987 that cultured TILs can kill tumor cells more than 100 times more effectively than T-cells cultured from peripheral blood in melanoma, it has been confirmed that cultured TILs can successfully cure clinical patients with melanoma. Since 1989, after we investigated TIL isolation performance from solid tumors, we modified some procedures to increase efficacy, and thus successfully established new TIL isolation and culture methods in 1994. Moreover, our laboratory and clinicians using our cultured TILs have published more than 30 papers. To improve the efficacy of TILs, we have been carrying out studies of TIL efficacy to treat solid tumor diseases for approximately 30 years. The three main questions of TIL study have been “How do TILs remain silent in solid tumor tissue?”, “How do TILs attack homologous and heterologous antigens from tumor cells of solid tumors?”, and “How do TILs infiltrate solid tumor tissue from a distance into tumor sites to kill tumor cells?”. Research on these three issues has increasingly answered these questions. In this review I summarize the main issues surrounding TILs in treating solid tumors. This review aims to study the killing function of TILs from solid tumor tissues, thereby ultimately introducing the optimal strategy for patients suffering from solid tumors through personalized immunotherapy in the near future.
Editor:
Frontiers Media S.A
Idioma:
Inglés
This feature requires javascript
This feature requires javascript
Volver a la lista de resultados
Anterior
Resultado
4
Siguiente
This feature requires javascript
This feature requires javascript
Buscando en bases de datos remotas, por favor espere
Buscando por
en
scope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
Mostrar lo que tiene hasta ahora
This feature requires javascript
This feature requires javascript